The success of microneedle-mediated vaccine delivery into skin

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 11, 2016, Pages 2975-2983

  Marshall, Sarah ^a   Sahm, Laura J ^a,b   Moore, Anne C ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

microneedle; skin; vaccine

Indexed keywords

INFLUENZA VACCINE; VACCINE;

COATED MICRONEEDLE; DEVELOPING COUNTRY; DISSOLVING MICRONEEDLE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; HOLLOW MICRONEEDLE; HUMAN; IMMUNOGENICITY; INFLUENZA; MICRONEEDLE; NONHUMAN; PUBLICATION; REVIEW; SCIENTIFIC LITERATURE; SKIN; SOLID MICRONEEDLE; THERMOSTABILITY; VACCINATION; ANIMAL; CUTANEOUS DRUG ADMINISTRATION; DEVICES; DISEASE MODEL; INTRADERMAL DRUG ADMINISTRATION; NEEDLE; PROCEDURES;

ADMINISTRATION, CUTANEOUS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRADERMAL; NEEDLES; VACCINES;

EID: 84997771260     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1171440     Document Type: Review

References (142)

1. Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deli Rev 2012; 64(14):1547-68; PMID:22575858; http://dx.doi.org/10.1016/j.addr.2012.04.005
2. Drucker E, Alcabes PG, Marx PA. The injection century:massive unsterile injections and the emergence of human pathogens. Lancet 2001; 358(9297):1989-92; PMID:11747942; http://dx.doi.org/10.1016/S0140-6736(01)06967-7
3. Kermode M. Unsafe injections in low-income country health settings:need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 2004; 19(1):95-103; PMID:14976177; http://dx.doi.org/10.1093/heapro/dah110
4. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15(1):7-16; PMID:14769164; http://dx.doi.org/10.1258/095646204322637182
5. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults:prevalence and associations. AmJ Trop Med Hyg 2003; 68(3):341-44; PMID:12685642
6. Hamilton JG. Needle phobia:a neglected diagnosis. J Fam Pract 1995; 41:169-75; PMID:7636457
7. Marks I. Blood-injury phobia:a review. Am J Psychiatry 1988; 145(10):1207-13; PMID:3048117; http://dx.doi.org/10.1176/ajp.145.10.1207
8. Kleinknecht RA. Acquisition of blood, injury, and needle fears and phobias. Behav Res Ther 1994; 32(8):817-23; PMID:7993325; http://dx.doi.org/10.1016/0005-7967(94)90161-9
9. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58(1):p. 68-89; PMID:16564111; http://dx.doi.org/10.1016/j.addr.2005.12.003
10. Wang L, Coppel RL. Oral vaccine delivery:can it protect against non-mucosal pathogens? Expert Rev Vaccines 2008; 7:729-38; PMID:18665772
11. Top FH, Buescher EL, Bancroft WH, Russell PK. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 1971; 124(2):155-60; PMID:4330998; http://dx.doi.org/10.1093/infdis/124.2.155
12. Bernstein DI. Rotarix:development of a live attenuated monovalent human rotavirus vaccine. Pediatr Ann 2006; 35(1):38; PMID:16466074; http://dx.doi.org/10.3928/0090-4481-20060101-12
13. Ciarlet M, Schödel F. Development of a rotavirus vaccine:clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq→. Vaccine 2009; 27:G72-81; PMID:20006144; http://dx.doi.org/10.1016/j.vaccine.2009.09.107
14. Germanier R, Fürer E. Characteristics of the attenuated oral vaccine strain“ S. typhi” Ty 21a. Dev Biol Stand 1982; 53:3-7; PMID:6873472
15. Liebowitz D, Lindbloom JD, Brandl JR, Garg SJ, Tucker SN. High titre neutralising antibodies to influenza after oral tablet immunisation:a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis 2015; 15(9):1041-8; PMID:26333337; http://dx.doi.org/10.1016/S1473-3099(15)00266-2
16. Bora P, Kumar L, Bansal AK. Microneedle technology for advanced drug delivery:Evolving vistas. Review Article, Deaprtment of Pharmaceutical Technology, NIPER, CRIPS 2008; 9(1).
17. Lambert PH, Laurent PE. Intradermal vaccine delivery:will new delivery systems transform vaccine administration? Vaccine 2008; 26(26):3197-208; PMID:18486285; http://dx.doi.org/10.1016/j.vaccine.2008.03.095
18. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, Wasi C. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000; 78(5):693-8; PMID:10859864
19. Hawkridge A, Hatherill M, Little F, Goetz MA, Barker L, Mahomed H, Sadoff J, Hanekom W, Geiter L, Hussey G, et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants:randomised trial. Bmj 2008; 337:a2052; PMID:19008268; http://dx.doi.org/10.1136/bmj.a2052
20. Emerging WHODO, Surveillance OCD. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies1997:World Health Organization, Division of Emerging and other Communicable Diseases Surveillance and Control.
21. Al Jarad N, Empey D, Duckworth G. Administration of the BCG vaccination using the multipuncture method in schoolchildren:a comparison with the intradermal method. Thorax 1999; 54(9):762-4; PMID:10456967; http://dx.doi.org/10.1136/thx.54.9.762
22. Ormerod L, Palmer C. Tuberculin reactivity after neonatal percutaneous BCG immunisation. Arch Dis Child 1993; 69(1):155; PMID:8024303; http://dx.doi.org/10.1136/adc.69.1.155
23. Donnelly RF, Singh TRR. Novel Delivery Systems for Transdermal and Intradermal Drug Delivery 2015:John Wiley & Sons.
24. Haq M, Smith E, John DN, Kalavala M, Edwards C, Anstey A, Morrissey A, Birchall JC. Clinical administration of microneedles:skin puncture, pain and sensation. Biomed Microdevices 2009; 11(1):35-47; PMID:18663579; http://dx.doi.org/10.1007/s10544-008-9208-1
25. Birchall JC, Clemo R, Anstey A, John DN. Microneedles in clinical practice–an exploratory study into the opinions of healthcare professionals and the public. Pharm Res 2011; 28(1):95-106; PMID:20238152; http://dx.doi.org/10.1007/s11095-010-0101-2
26. Escobar‐Chávez JJ, Bonilla-Martínez D, Villegas-González MA, Molina-Trinidad E, Casas-Alancaster N, Revilla-Vázquez AL. Microneedles:a valuable physical enhancer to increase transdermal drug delivery. J Clin Pharmacol 2011; 51(7):964-977; PMID:21148047; http://dx.doi.org/10.1177/0091270010378859
27. Birchall JC. Microneedle array technology:the time is right but is the science ready? Expert Rev Med Devices 2006; 3(1):1-4; PMID:16359245; http://dx.doi.org/10.1586/17434440.3.1.1
28. Norman JJ, Prausnitz MR. Improving patient acceptance of insulin therapy by improving needle design. J Diabetes Sci Technol 2012; 6(2):336-8; PMID:22538143; http://dx.doi.org/10.1177/193229681200600217
29. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27(3):454-9; PMID:19022318; http://dx.doi.org/10.1016/j.vaccine.2008.10.077
30. Al-Zahrani S, Zaric M, McCrudden C, Scott C, Kissenpfennig A, Donnelly RF. Microneedle-mediated vaccine delivery:harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv 2012; 9(5):541-50; PMID:22475249; http://dx.doi.org/10.1517/17425247.2012.676038
31. Mistilis MJ, Bommarius AS, Prausnitz MR. Development of a Thermostable Microneedle Patch for Influenza Vaccination. J Pharm Sci 2015; 104(2):740-9; PMID:25448542; http://dx.doi.org/10.1002/jps.24283
32. Choi H-J, Yoo DG, Bondy BJ, Quan FS, Compans RW, Kang SM, Prausnitz MR. Stability of influenza vaccine coated onto microneedles. Biomaterials 2012; 33(14):3756-69; PMID:22361098; http://dx.doi.org/10.1016/j.biomaterials.2012.01.054
33. Chen X, Fernando GJ, Crichton ML, Flaim C, Yukiko SR, Fairmaid EJ, Corbett HJ, Primiero CA, Ansaldo AB, Frazer IH. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release 2011; 152(3):349-55; PMID:21371510; http://dx.doi.org/10.1016/j.jconrel.2011.02.026
34. Jepps OG, Dancik Y, Anissimov YG, Roberts MS. Modeling the human skin barrier—Towards a better understanding of dermal absorption. Adv Drug Deliv Rev 2013; 65(2):152-68; PMID:22525516; http://dx.doi.org/10.1016/j.addr.2012.04.003
35. Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 2006; 24(35):6110-19; PMID:16766095; http://dx.doi.org/10.1016/j.vaccine.2006.05.014
36. Salmon J, Armstrong C, Ansel J. The skin as an immune organ. West J Med 1994; 160(2):146; PMID:8160465
37. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673):245-252; PMID:9521319; http://dx.doi.org/10.1038/32588
38. Steinman RM. Dendritic cells and the control of immunity:enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68(3):160-166; PMID:11373688
39. Schroder JM, Reich K, Kabashima K, Liu FT, Romani N, Metz M, Kerstan A, Lee PH, Loser K, Schon MP, Maurer M, Stoitzner P, Beissert S, Tokura Y, Gallo RL. Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes? Exp Dermatol 2006; 15(11):913–6.
40. Lee HK, Iwasaki A. Innate control of adaptive immunity:dendritic cells and beyond. in Seminars in immunology 2007:Elsevier.
41. Zachariae CO, Thestrup-Pedersen K, Matsushima K. Expression and secretion of leukocyte chemotactic cytokines by normal human melanocytes and melanoma cells. J Invest Dermatol 1991; 97(3):593-9; PMID:1875058; http://dx.doi.org/10.1111/1523-1747.ep12481934
42. Urb M, Sheppard DC. The role of mast cells in the defence against pathogens. PLoS Pathog 2012; 8(4):e1002619; PMID:22577358; http://dx.doi.org/10.1371/journal.ppat.1002619
43. Abraham SN, John ALS. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10(6):440-52; PMID:20498670; http://dx.doi.org/10.1038/nri2782
44. Koutsonanos DG, Esser ES, McMaster SR, Kalluri P, Lee JW, Prausnitz MR, Skountzou I, Denning TL, Kohlmeier JE, Compans RW. Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. Vaccine 2015; 33:4675-82; PMID:25744228
45. Bal SM, Ding Z, Kersten GF, Jiskoot W, Bouwstra JA. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm Res 2010; 27(9):1837-47; PMID:20559701; http://dx.doi.org/10.1007/s11095-010-0182-y
46. Ding Z, Verbaan FJ, Bivas-Benita M, Bungener L, Huckriede A, van den Berg DJ, Kersten G, Bouwstra JA. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release 2009; 136(1):71-78; PMID:19331846; http://dx.doi.org/10.1016/j.jconrel.2009.01.025
47. Guo L, Qiu Y, Chen J, Zhang S, Xu B, Gao Y. Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays. Biomed Microdevices 2013; 15(6):1077-85; PMID:23893014; http://dx.doi.org/10.1007/s10544-013-9799-z
48. Ding Z, Van Riet E, Romeijn S, Kersten GF, Jiskoot W, Bouwstra JA. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm Res 2009; 26(7):1635-43; PMID:19326190; http://dx.doi.org/10.1007/s11095-009-9874-6
49. Hirschberg H, van Kuijk S, Loch J, Jiskoot W, Bouwstra J, Kersten G, Amorij JP. A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus. Eur J Pharm Sci 2012; 46(1):1-7; PMID:22330147; http://dx.doi.org/10.1016/j.ejps.2012.01.013
50. Yin D, Liang W, Xing S, Gao Z, Zhang W, Guo Z, Gao S. Hepatitis B DNA vaccine-polycation nano-complexes enhancing immune response by percutaneous administration with microneedle. Biol Pharm Bull 2013; 36(8):1283-91; PMID:23676787; http://dx.doi.org/10.1248/bpb.b13-00050
51. Carey JB, Vrdoljak A, O'Mahony C, Hill AV, Draper SJ, Moore AC. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci Rep 2014; 4:6154; PMID:25142082; http://dx.doi.org/10.1038/srep06154
52. Pearson FE, O'Mahony C, Moore AC, Hill AV. Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine 2015; 33:3248-55 PMID:2583910
53. Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker JP, 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M. Protective immunization against inhalational anthrax:a comparison of minimally invasive delivery platforms. J Infect Dis 2005; 191(2):278-88; PMID:15609239; http://dx.doi.org/10.1086/426865
54. Kim Y-C, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 2010; 142(2):187-95; PMID:19840825; http://dx.doi.org/10.1016/j.jconrel.2009.10.013
55. Kim Y-C, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 2010; 11(3):1193-201; PMID:20676947; http://dx.doi.org/10.1208/s12249-010-9471-3
56. Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, Guirakhoo F, Monath TP, Mikszta JA. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccines against Japanese encephalitis (ChimeriVaxTM-JE) in non-human primates. Hum Vaccin 2005; 1(3):106-11; PMID:17012854; http://dx.doi.org/10.4161/hv.1.3.1797
57. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25(52):8833-42; PMID:18023942; http://dx.doi.org/10.1016/j.vaccine.2007.10.020
58. Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 2010; 28(36):5850-6; PMID:20600481; http://dx.doi.org/10.1016/j.vaccine.2010.06.062
59. Kim Y-C, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009; 27(49):6932-8; PMID:19761836; http://dx.doi.org/10.1016/j.vaccine.2009.08.108
60. Kim Y-C, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010; 201(2):190-8; PMID:20017632; http://dx.doi.org/10.1086/649228
61. Kim Y-C, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release 2013; 172(2):579-88; PMID:23643528; http://dx.doi.org/10.1016/j.jconrel.2013.04.016
62. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I. Transdermal influenza immunization with vaccine-coated microneedle arrays. PloS one 2009; 4(3):e4773; PMID:19274084; http://dx.doi.org/10.1371/journal.pone.0004773
63. Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, Pan L, Skountzou I, Gill HS, Prausnitz MR, Yang C, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 2009; 106(19):7968-73; PMID:19416832; http://dx.doi.org/10.1073/pnas.0812652106
64. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol 2011; 18(4):647-54; PMID:21288996; http://dx.doi.org/10.1128/CVI.00435-10
65. Wang B-Z, Gill HS, He C, Ou C, Wang L, Wang YC, Feng H, Zhang H, Prausnitz MR, Compans RW. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release 2014; 178:1-7; PMID:24417966; http://dx.doi.org/10.1016/j.jconrel.2014.01.002
66. Song J-M, Kim YC, Lipatov AS, Pearton M, Davis CT, Yoo DG, Park KM, Chen LM, Quan FS, Birchall JC, et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B-and T-cell responses in mice. Clin Vaccine Immunol 2010; 17(9):1381-9; PMID:20631330; http://dx.doi.org/10.1128/CVI.00100-10
67. Song J-M, Kim YC, O E, Compans RW, Prausnitz MR, Kang SM. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther 2012; 20(7):1472-80; PMID:22508490; http://dx.doi.org/10.1038/mt.2012.69
68. Song J-M, Kim YC, Barlow PG, Hossain MJ, Park KM, Donis RO, Prausnitz MR, Compans RW, Kang SM. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010; 88(2):244-7; PMID:20851715; http://dx.doi.org/10.1016/j.antiviral.2010.09.001
69. Shin J-H, Park JK, Lee DH, Quan FS, Song CS, Kim YC. Microneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination against Swine-Origin Influenza A (H1N1) in Mice. PloS one 2015; 10(6):e0130684; PMID:26086590; http://dx.doi.org/10.1371/journal.pone.0130684
70. Quan F-S, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PloS one 2009; 4(9):e7152; PMID:19779615; http://dx.doi.org/10.1371/journal.pone.0007152
71. Quan F-S, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, Compans RW, Kang SM. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 2010; 84(15):7760-9; PMID:20484519; http://dx.doi.org/10.1128/JVI.01849-09
72. Quan F-S, Kim YC, Song JM, Hwang HS, Compans RW, Prausnitz MR, Kang SM. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol 2013; 20(9):1433-9; PMID:23863506; http://dx.doi.org/10.1128/CVI.00251-13
73. Quan F-S, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010; 147(3):326-32; PMID:20692307; http://dx.doi.org/10.1016/j.jconrel.2010.07.125
74. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, Prausnitz MR, Compans RW, Skountzou I. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012; 2:357;PMID:22500210; http://dx.doi.org/10.1038/srep00357
75. Kim Y-C, Song JM, Lipatov AS, Choi SO, Lee JW, Donis RO, Compans RW, Kang SM, Prausnitz MR. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm 2012; 81(2):239-47; PMID:22504442; http://dx.doi.org/10.1016/j.ejpb.2012.03.010
76. Kim MC, Lee JW, Choi HJ, Lee YN, Hwang HS, Lee J, Kim C, Lee JS, Montemango C, Prausnitz MR, Kang SM. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Control Release 2015; 210:208–16.
77. del Pilar Martin M, Weldon WC, Zarnitsyn VG, Koutsonanos DG, Akbari H, Skountzou I, Jacob J, Prausnitz MR, Compans RW. Local response to microneedle-based influenza immunization in the skin. MBio 2012; 3(2):e00012-12; PMID:22396479; http://dx.doi.org/10.1128/mBio.00012-12
78. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One 2010; 5(10):e13460; PMID:20976136; http://dx.doi.org/10.1371/journal.pone.0013460
79. Kines RC, Zarnitsyn V, Johnson TR, Pang YY, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR. Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles. PloS one 2015; 10(3):e0120797; PMID:25785935; http://dx.doi.org/10.1371/journal.pone.0120797
80. Prow TW, Chen X, Prow NA, Fernando GJ, Tan CS, Raphael AP, Chang D, Ruutu MP, Jenkins DW, Pyke A, et al. Nanopatch‐Targeted Skin Vaccination against West Nile Virus and Chikungunya Virus in Mice. Small 2010; 6(16):1776-84; PMID:20665754; http://dx.doi.org/10.1002/smll.201000331
81. Moon S, Wang Y, Edens C, Gentsch JR, Prausnitz MR, Jiang B. Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine 2013; 31(34):3396-402; PMID:23174199; http://dx.doi.org/10.1016/j.vaccine.2012.11.027
82. Chen X, Kask AS, Crichton ML, McNeilly C, Yukiko S, Dong L, Marshak JO, Jarrahian C, Fernando GJ, Chen D, et al. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J Control Release 2010; 148(3):327-33; PMID:20850487; http://dx.doi.org/10.1016/j.jconrel.2010.09.001
83. Gill HS, Söderholm J, Prausnitz MR, Sällberg M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene therapy 2010; 17(6):811-4; PMID:20200562; http://dx.doi.org/10.1038/gt.2010.22
84. Kommareddy S, Baudner BC, Bonificio A, Gallorini S, Palladino G, Determan AS, Dohmeier DM, Kroells KD, Sternjohn JR, Singh M, et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 2013; 31(34):3435-41; PMID:23398932; http://dx.doi.org/10.1016/j.vaccine.2013.01.050
85. Hiraishi Y, Nandakumar S, Choi SO, Lee JW, Kim YC, Posey JE, Sable SB, Prausnitz MR. Bacillus Calmette-Guerin vaccination using a microneedle patch. Vaccine 2011; 29(14):2626-36; PMID:21277407; http://dx.doi.org/10.1016/j.vaccine.2011.01.042
86. Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G. Poly [di (carboxylatophenoxy) phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 2009; 106(45):18936-41; PMID:19864632; http://dx.doi.org/10.1073/pnas.0908842106
87. Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine 2013; 31(34):3403-9; PMID:23044406; http://dx.doi.org/10.1016/j.vaccine.2012.09.062
88. van der Maaden K, Sekerdag E, Schipper P, Kersten G, Jiskoot W, Bouwstra J. Layer-by-layer assembly of inactivated poliovirus and N-trimethyl chitosan on pH-sensitive microneedles for dermal vaccination. Langmuir 2015; 31(31):8654-60; PMID:26145437; http://dx.doi.org/10.1021/acs.langmuir.5b01262
89. Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis 2015; 211(12):1969-76; PMID:25567841; http://dx.doi.org/10.1093/infdis/jiu841
90. Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device:A randomized controlled trial. Vaccine 2015; 33:6816-22; PMID:26476367
91. Atmar RL, Patel SM, Keitel WA. Intanza(®):A new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 2010; 9(12):1399–409.
92. Leroux-Roels I, Weber F. Intanza→ 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Hum Vaccin & immunotherapeutics 2013; 9(1):115-21; PMID:23442585; http://dx.doi.org/10.4161/hv.22342
93. Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, Evans M, Stewart T, Amemiya K, Ulrich RG, et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol 2009; 16(5):719-25; PMID:19261773; http://dx.doi.org/10.1128/CVI.00447-08
94. van der Maaden K, Trietsch SJ, Kraan H, Varypataki EM, Romeijn S, Zwier R, van der Linden HJ, Kersten G, Hankemeier T, Jiskoot W, et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination:a study with polio vaccine in rats. Pharm Res 2014; 31(7):1846-154; PMID:24469907
95. Hirobe S, Azukizawa H, Hanafusa T, Matsuo K, Quan YS, Kamiyama F, Katayama I, Okada N, Nakagawa S. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials 2015; 57:50-8; PMID:25913250; http://dx.doi.org/10.1016/j.biomaterials.2015.04.007
96. Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'Hagan DT. Dissolvable microneedle patches for the delivery of cell‐culture‐derived influenza vaccine antigens. J Pharm Sci 2012; 101(3):1021-7; PMID:22190403; http://dx.doi.org/10.1002/jps.23019
97. Matsuo K, Hirobe S, Yokota Y, Ayabe Y, Seto M, Quan YS, Kamiyama F, Tougan T, Horii T, Mukai Y, et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Control Release 2012; 160(3):495-501; PMID:22516091; http://dx.doi.org/10.1016/j.jconrel.2012.04.001
98. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, Murthy N, Compans RW, Skountzou I, Prausnitz MR. Dissolving polymer microneedle patches for influenza vaccination. Nature medicine 2010; 16(8):915-20; PMID:20639891; http://dx.doi.org/10.1038/nm.2182
99. Vassilieva EV, Kalluri H, McAllister D, Taherbhai MT, Esser ES, Pewin WP, Pulit-Penaloza JA, Prausnitz MR, Compans RW, Skountzou I. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res 2015; 5(4):360–71.
100. Wang J, Li B, Wu MX. Effective and lesion-free cutaneous influenza vaccination. Proc Natl Acad Sci U S A 2015; 112(16):5005-10; PMID:25848020; http://dx.doi.org/10.1073/pnas.1500408112
101. Qiu Y, Guo L, Zhang S, Xu B, Gao Y, Hu Y, Hou J, Bai B, Shen H, Mao P. DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN. Drug Deliv 2015:1–8 [Epub ahead of print]
102. Wang T, Zhen Y, Ma X, Wei B, Li S, Wang N. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain. Colloids Surf Biointerfaces 2015; 126:520-30; PMID:25612819; http://dx.doi.org/10.1016/j.colsurfb.2015.01.005
103. Pattani A, McKay PF, Garland MJ, Curran RM, Migalska K, Cassidy CM, Malcolm RK, Shattock RJ, McCarthy HO, Donnelly RF. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release 2012; 162(3):529–37.
104. Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine 2015; 33:4712-8; PMID:25770786
105. Edens C, Dybdahl-Sissoko NC, Weldon WC, Oberste MS, Prausnitz MR. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine 2015; 33:4683-90; PMID:25749246
106. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release 2007; 117(2):227-37; PMID:17169459; http://dx.doi.org/10.1016/j.jconrel.2006.10.017
107. Vrdoljak A, McGrath MG, Carey JB, Draper SJ, Hill AV, O'Mahony C, Crean AM, Moore AC. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 2012; 159(1):34-42; PMID:22245683; http://dx.doi.org/10.1016/j.jconrel.2011.12.026
108. Wonglertnirant N, Todo H, Opanasopit P, Ngawhirunpat T, Sugibayashi K. Macromolecular delivery into skin using a hollow microneedle. Biol Pharm Bull 2010; 33(12):1988-93; PMID:21139238; http://dx.doi.org/10.1248/bpb.33.1988
109. Davis SP, Martanto W, Allen MG, Prausnitz MR. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng 2005; 52(5):909–15.
110. Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res 2011; 28(1):107-16; PMID:20354765; http://dx.doi.org/10.1007/s11095-010-0123-9
111. Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater 2008; 20(5):933-8; PMID:23239904; http://dx.doi.org/10.1002/adma.200701205
112. Lee JW, Park J-H, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008; 29(13):2113-24; PMID:18261792; http://dx.doi.org/10.1016/j.biomaterials.2007.12.048
113. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26(11):p. 1261-1268; PMID:18997767; http://dx.doi.org/10.1038/nbt.1504
114. Lahiji SF, Dangol M, Jung H. A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery. Sci Rep2015; 5:7914; PMID:25604728; http://dx.doi.org/10.1038/srep07914
115. Donnelly RF, Singh TRR, Woolfson AD. Microneedle-based drug delivery systems:microfabrication, drug delivery, and safety. Drug Deliv 2010; 17(4):187-207; PMID:20297904; http://dx.doi.org/10.3109/10717541003667798
116. McGrath MG, Vucen S, Vrdoljak A, Kelly A, O'Mahony C, Crean AM, Moore A. Production of dissolvable microneedles using an atomised spray process:Effect of microneedle composition on skin penetration. Eur J Pharm Biopharm 2014; 86(2):200-11; PMID:23727511; http://dx.doi.org/10.1016/j.ejpb.2013.04.023
117. Chu LY, Choi SO, Prausnitz MR. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery:bubble and pedestal microneedle designs. J Pharm Sci 2010; 99(10):4228-38; PMID:20737630; http://dx.doi.org/10.1002/jps.22140
118. Lutton RE, et al. Microneedle characterisation:the need for universal acceptance criteria and GMP specifications when moving towards commercialisation. Drug Deliv Transl Res 2015:p. 1-19.
119. WHO. Vaccine-preventable diseases 2015 [cited 2015 24th November]; Available from:http://apps.who.int/immunization_monitoring/diseases/en/.
120. Mikszta JA, Dekker JP, 3rd, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CJ, Ulrich RG. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 2006; 74(12):6806-10; PMID:17030580; http://dx.doi.org/10.1128/IAI.01210-06
121. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Influenza-and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J 2007; 30(6):1158-66; PMID:17715167; http://dx.doi.org/10.1183/09031936.00034407
122. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006; (3):CD004876.
123. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. Jama 2004; 292(11):1333-40; PMID:15367555; http://dx.doi.org/10.1001/jama.292.11.1333
124. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin Infect Dis 2012; 54(10):1427-36; PMID:22495079; http://dx.doi.org/10.1093/cid/cis211
125. Chaves SS, Lynfield R, Lindegren ML, Bresee J, Finelli L. The US influenza hospitalization surveillance network. Emerg Infect Dis 2015; 9:1543-50; PMID:26291121; http://dx.doi.org/10.3201/eid2109.141912
126. Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, Butler L, Baumbach J, Hollick G, Bennett NM, et al. Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. PloS one 2015; 10(3):e0118369; PMID:25738736; http://dx.doi.org/10.1371/journal.pone.0118369
127. Treanor J. Influenza vaccine—outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350(3):218-20; PMID:14724300; http://dx.doi.org/10.1056/NEJMp038238
128. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; (3):CD001269.
129. Executive Board, Prevention and control of influenza pandemics and annual epidemics 2003.
130. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009; 58(6):446-58; PMID:19446340; http://dx.doi.org/10.1016/j.jinf.2009.04.001
131. CDC:Flu vaccination coverage, United States, 2014 -15 influenza season. 2015. Available from:http://www.cdc.gov/flu/fluvaxview/coverage-1415estimates.htm
132. Noh JY, Kim WJ. Influenza vaccines:unmet needs and recent developments. Infect Chemother 2013; 45(4):375-86; PMID:24475351; http://dx.doi.org/10.3947/ic.2013.45.4.375
133. Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches:usability and acceptability for self-vaccination against influenza. Vaccine 2014; 32(16):1856-62; PMID:24530146; http://dx.doi.org/10.1016/j.vaccine.2014.01.076
134. Miller MA, Sentz JT. Chapter 12 Vaccine-Preventable Diseases. In Disease and mortality in sub-Saharan Africa. 2nd edition. Washington, DC:The International Bank for Reconstruction and Development/World Bank; 2006.
135. Ren Q, Xiong H, Li Y, Xu R, Zhu C. Evaluation of an outside-the-cold-chain vaccine delivery strategy in remote regions of western China. Public Health Rep 2009; 124(5):745; PMID:19753953
136. Wang L, Li J, Chen H, Li F, Armstrong GL, Nelson C, Ze W, Shapiro CN. Hepatitis B vaccination of newborn infants in rural China:evaluation of a village-based, out-of-cold-chain delivery strategy. Bull World Health Organ 2007; 85(9):688-94; PMID:18026625; http://dx.doi.org/10.2471/BLT.06.037002
137. Dowling JM, Yap CF. Happiness and poverty in developing countries:A global perspective 2012:Palgrave Macmillan.
138. Naicker S, Plange-Rhule J, Tutt RC, Eastwood JB. Shortage of healthcare workers in developing countries–Africa. Ethn Dis 2009; 19(1 Suppl 1):S1-60-4.
139. Wolfe DN, Florence W, Bryant P. Current biodefense vaccine programs and challenges. Hum Vaccin Immunother 2013; 9(7):1591-7; PMID:23428906; http://dx.doi.org/10.4161/hv.24063
140. Moga KA, Bickford LR, Geil RD, Dunn SS, Pandya AA, Wang Y, Fain JH, Archuleta CF, O'Neill AT, Desimone JM. Rapidly–dissolvable microneedle patches via a highly scalable and reproducible soft lithography approach. Adv Mater 2013; 25(36):5060-6; PMID:23893866; http://dx.doi.org/10.1002/adma.201300526
141. Lutton RE, Larrañeta E, Kearney MC, Boyd P, Woolfson AD, Donnelly RF. A novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays. Int J Pharm 2015; 494(1):417-29; PMID:26302858; http://dx.doi.org/10.1016/j.ijpharm.2015.08.049
142. Weldon WC, Zarnitsyn VG, Esser ES, Taherbhai MT, Koutsonanos DG, Vassilieva EV, Skountzou I, Prausnitz MR, Compans RW. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PloS one 2012; 7(7):e41501; PMID:22848514; http://dx.doi.org/10.1371/journal.pone.0041501